US vaccine guidance stalls as federal advisory committee remains vacant

The United States immunization system has entered a state of administrative uncertainty after a federal court halted the dismantling of its primary advisory body. The Advisory Committee on Immunization Practices, or ACIP, currently has no members. This vacancy means new vaccines approved by the Food and Drug Administration lack the official endorsement required for full insurance coverage and broad distribution in many states.

Secretary of Health and Human Services Robert F. Kennedy Jr. restructured the committee earlier in the administration. He reduced childhood immunization recommendations by one-third and replaced independent experts with political allies. A federal judge subsequently ruled that these changes were procedurally flawed and ordered the committee reconstituted. Kennedy has not nominated new members since that ruling. As a result, the panel remains empty while new vaccines continue to receive FDA approval.

The immediate impact is visible in patient experiences. Ron Kroening, a 63-year-old asthmatic in Oklahoma, sought Moderna’s new mRNA flu vaccine for the current season. The FDA approved this shot for adults over 50 in August. Trials indicated it provides stronger protection than traditional flu vaccines. Kroening found only one local pharmacy with stock. His insurer denied the claim because the vaccine lacks an ACIP recommendation. He paid a $40 co-pay out of pocket.

Insurers typically add coverage for new vaccines within a year or more of FDA approval. However, the standard trigger is an ACIP recommendation. A recommendation made in December 2026 would generally require coverage by the 2028 plan year. A recommendation in January 2027 would delay coverage until January 2029. Lindsay Wiley, a law professor at UCLA, noted that the legal mandate for coverage does not activate immediately. She described a recommendation next year as the best-case scenario for the new flu shot, though she does not expect one soon.

Congress created a specific exception for coronavirus vaccines. An amendment to the Affordable Care Act requires insurers to cover these shots within 15 days of an ACIP recommendation. This statutory requirement does not apply to other vaccines. The lack of a standing committee also affects state-level practices. Some states prohibit pharmacists from administering vaccines without an ACIP recommendation. This gap has created delays in Medicare coverage for senior flu shots, even though existing law mandates coverage without a formal recommendation.

The government is appealing the portion of the court order that disbanded the committee. Aaron Siri, a lawyer who represented Kennedy, stated on Monday that the White House and the Department of Justice are not making a serious attempt to revive the panel. Dorit Reiss, a vaccines expert at UC Law San Francisco, agreed that the federal government is choosing to keep the committee empty. She suggested the vacancy may suit Kennedy, whose original appointees did not implement schedule changes as quickly as desired.

Reiss warned that bypassing the ACIP allows the secretary to make unilateral recommendations. She also noted that public trust in the committee’s independence has been damaged. Restoring the body may require new legislation to protect its status from future political interference. The committee’s previous decisions, including a September 2025 recommendation on RSV shots, were halted by the court order, although insurers appear to be covering those vaccines anyway.

Kroening’s insurer is part of the Association of Health Insurance Providers, which has pledged to continue covering shots recommended as of September 2025. Kroening said he would choose the new vaccine again and is glad he paid for it. He remains unhappy that his insurance did not cover the cost. "It's a mess right now, what they're doing with our vaccines," he said.